News

Novo Nordisk Stock Tumbles 20% After Ozempic Maker’s Shock Cut to U.S. Outlook
The drugmaker unexpectedly cuts its full-year guidance, citing lower sales expectations for its blockbuster drugs Wegovy and ...
Obesity drugmaker Novo Nordisk picks Maziar Mike Doustdar as new CEO
Novo Nordisk named Maziar Mike Doustdar as its new chief executive on Tuesday, relying on an experienced company insider to ...
Legit on MSN8m
Novo Nordisk cuts earning forecasts again, names new CEO
Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, on Tuesday ...
Weight-loss patients taking Zepbound forced to switch to Wegovy after drop in coverage
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
Novo Nordisk faces 'show me' moment to boost Wegovy growth after US copycat ban
A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will ...
Devdiscourse1d
Novo Nordisk's Wegovy: Battling Market Challenges Amid Rising Prescriptions
The U.S. FDA ban on compounded versions of Novo Nordisk's Wegovy has increased its prescriptions by 33%. Despite this, ...
Novo Nordisk Bets Big on India, creates new jobs
Novo Nordisk has launched its anti-obesity drug Wegovy in India, which has become a key market for the company. Having ...
Fierce Pharma4d
Viatris beats Novo in semaglutide patent feud, clearing hurdle for potential Wegovy generic
After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...